

Janssen Research & Development
Global Regulatory Affairs

920 US Highway 202
Raritan, NJ 08869
908-927-4917 tel
908-927-7901 fax



March 19, 2013

To whom it may concern

Products:

R004263 F904 DUROGESIC Matrix(A)fentanyl 12 µg/h(Transdermal)(patch)
R004263 F900 DUROGESIC Matrix(A)fentanyl 25µg/h(Transdermal)(patch)
R004263 F901 DUROGESIC Matrix(A)fentanyl 50 µg/h(Transdermal)(patch)
R004263 F902 DUROGESIC Matrix(A)fentanyl 75 µg/h(Transdermal)(patch)
R004263 F903 DUROGESIC Matrix(A)fentanyl 100 µg/h(Transdermal)(patch)

Janssen Pharmaceutica NV confirms, for the products listed above, that the dosage form, container closure and labelling components do not contain latex/synthetic rubber as an ingredient; however, we cannot guarantee that the materials do not come in contact with latex/synthetic rubber during the manufacturing or packaging process (e.g. latex gloves).

CAROLYN GERHARDT

Digitally signed by CAROLYN GERHARDT
DN: c=US, o=JNJ, ou=Employees, ou=180527,
cn=CAROLYN GERHARDT, email=CGERHARD@its.jnj.com
Reason: I am the author of this document.
Date: 2013.03.19 08:40:03 -07'00'

Carolyn Gerhardt
Associate Director
Janssen Research and Development, LLC